[The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
Proarrhythmic action of an antiarrhythmic drug is defined as 1) Worsening of preexisting arrhythmia (for example, increase of number of premature beats; frequency, rate, and duration of tachycardias at supraventricular or ventricular level); 2) induction of arrhythmias (supraventricular: for example, atrial tachycardia with block; ventricular: monomorphic or polymorphic ventricular tachycardia, torsade de pointes, ventricular fibrillation); 3) occurrence of bradycardia (sick sinus syndrome; atrioventricular and intraventricular conduction disturbances). The pathophysiology of proarrhythmic action is either facilitation of conduction block and reentry, or abnormal impulse formation. Induction of incessant monomorphic ventricular tachycardia or torsade de pointes is of special clinical relevance. Incessant ventricular tachycardia can be experimentally explained by an increase of functional conduction block and decrease of the wavelength of excitation (conduction velocity x refractory period) as actions favoring reentry; this is clinically most frequently seen with the application of class IC (and A)-drugs. Abnormal QT prolongation and torsade de pointes are most likely due to early afterdepolarizations of the cell membrane, and development of triggered activity; these arrhythmias are seen following the application of substances prolonging repolarization (class III and class IA-antiarrhythmic drugs). Independent of the precise electrophysiologic mechanism, arrhythmias may, under clinical conditions, also be provoked secondary to the negative inotropic action of these drugs. Proarrhythmic actions most frequently are concentration-dependent; rarely are they idiosyncratic. Usually, these side-effects are seen during the first days after initiation or increase of the antiarrhythmic drug dose; they may, however, manifest themselves only after a couple of months.(ABSTRACT TRUNCATED AT 250 WORDS)
Steinbeck
G
G
Medizinische Klinik I, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000188:drug therapy; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004562:Electrocardiography / Q000187:drug effects; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D012307:Risk Factors
D000889:Anti-Arrhythmia Agents
Proarrhythmische Wirkungen von Antiarrhythmika--theoretische und klinische Aspekte.